Predicting Drug Shortages Before They Happen: 2026 Signals Every Buyer Should Watch
Drug shortages rarely come without warning. The signals are there in wholesaler allocation notices, upstream ingredient sourcing, trade policy filings, and dosage form economics long before a product lands on the FDA shortage database. Procurement teams have to know what to look for and when.
Here are four signals worth tracking now.
The FDA Database Is a Lagging Indicator
A shortage listing confirms a problem that has already materialized. The FDA's own guidance notes that localized supply gaps are sometimes the earliest signal of a national shortage, and that direct reports from buyers can prompt the agency to contact manufacturers before a disruption widens. For procurement teams, local availability problems should be treated as data, not one-off inconveniences.
Signal 1: Wholesaler Allocation and Fill Rates
Before a manufacturer reports an issue, wholesaler behavior changes. "No ship" notices, allocation restrictions, and fill rates dropping below 80% are measurable early indicators that supply is tightening. These signals appear at the ordering level before they reach any public database.
ASHP recommends assigning clear ownership to shortage monitoring: one person responsible for tracking triggers, confirming on-hand inventory, and escalating when thresholds are crossed. Without it, early warnings get buried in email threads. With it, a fill-rate dip on a specific NDC becomes actionable information.
Signal 2: Upstream API and Key Starting Material Concentration
Most shortage risk analysis focuses on finished-dose manufacturers. The more dangerous vulnerability sits further upstream, at the key starting material (KSM) level.
According to a 2026 USP vulnerability assessment, 48 of the 100 drugs on its updated Vulnerable Medicines List rely on a KSM sourced from a single country. A drug may have multiple API and finished-dose manufacturers across several countries, but if every one of them sources the same KSM from a single facility, any disruption cascades through the entire downstream chain simultaneously. Supplier diversity at the finished-dose level does not eliminate concentration risk if the ingredient tier is bottlenecked.
For buyers, knowing where a product's API originates is a meaningful input to sourcing decisions.
Signal 3: Policy and Tariff Developments
Trade policy has become a live supply chain variable. In April 2025, the U.S. Department of Commerce launched a Section 232 national security investigation into pharmaceutical imports, including finished drugs, APIs, and key starting materials. The investigation progressed to tariffs with rates varying by country and subject to ongoing negotiations, with exemptions that have not consistently extended to APIs and intermediates.
Monitoring Federal Register notices and trade policy updates should be part of a procurement team's standard workflow, not something filtered through a compliance department weeks after the fact. When tariff exposure shifts for a key API source country, the downstream supply risk changes with it.
Signal 4: Injectable Concentration Risk
Not all shortage risk is distributed evenly across drug categories. Injectables account for 63% of the drugs flagged on the USP Vulnerable Medicines List, driven by manufacturing complexity, strict sterility requirements, and limited production capacity that cannot scale quickly during demand spikes.
The economics compound the problem. Of the 98 active drug shortages tracked in 2024, 69% were sterile injectables, and 44% of those carried a price point below $5 per unit. At those margins, manufacturers have limited incentive to maintain buffer inventory, and facilities have little financial cushion to absorb a quality event or production disruption. Buyers with injectable-heavy portfolios should apply tighter monitoring windows and maintain backup sourcing relationships as standard practice.
Building a Predictive Posture
Reactive procurement is not a strategy, it is a cost. Tracking wholesaler fill rates, understanding upstream API sourcing geography, following policy developments, and flagging injectable vulnerabilities applies structured attention to the right indicators at the right time. Suppliers who provide transparency into their own supply chain are a meaningful part of that equation.
Contact us to learn how we can help you ensure an adequate inventory through our ample product availability and reliable sourcing.
